V114 clinical trials
- studies test it
- 6
- open now
- 0
- in phase 3
- 0
- first study started
- 2009
How each study uses V114 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
6 studies that test it; most in 2015 (2)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2010 | 1 |
| 2014 | 1 |
| 2015 | 2 |
| 2017 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Studies
Open first, then newest update. How each study uses V114 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Lots of V114 in Healthy Infants (V114-008)CompletedPhase 2Merck Sharp & Dohme LLCNCT02987972Written as V114 Lot 1
- Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-004)CompletedPhase 1/2Merck Sharp & Dohme LLCNCT02037984Written as V114 1x:1x:1x
- A Study of Pneumococcal Conjugate Vaccine (V114) Compared to a Marketed Vaccine (V114-003)CompletedPhase 2Merck Sharp & Dohme LLCNCT01215188Written as V114 Aluminum-adjuvanted
- Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)CompletedPhase 2Merck Sharp & Dohme LLCNCT02547649Written as V114-A
- A Study to Evaluate the Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-005)CompletedPhase 1/2Merck Sharp & Dohme LLCNCT02531373Written as V114 Medium Dose
- Safety and Tolerability Study for the Pneumococcal Conjugate Vaccine V114 Versus Prevnar™ (V114-001)CompletedPhase 1Merck Sharp & Dohme LLCNCT01215175Written as V114, Aluminum Adjuvanted